SIMPLY SOLVENTLESS ANNOUNCES Q1 2025 FINANCIAL RESULTS INCLUDING RECORD ANNUALIZED GROSS REVENUE OF $49.6 MILLION ($0.459/SHARE) AND ANNUALIZED ADJUSTED EBITDA OF $12.8 MILLION ($0.120/SHARE)
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
CALGARY, AB, June 20, 2025 /CNW/ - Simply Solventless Concentrates Ltd. (TSXV: HASH) (" SSC") is pleased to announce its Q1 2025 financial and operating results including record quarterly gross revenue of $12.4 million, EBITDA of $9.5 million, net and comprehensive income of $8.4 million, and adjusted EBITDA of $3.2 million. These results represent annualized gross revenue of $49.6 million ($0.459/share) and annualized adjusted EBITDA of $12.8 million ($0.120/share). The information set out in this press release should be read in conjunction with SSC's condensed interim consolidated financial statements as at and for the three months ended March 31, 2025 and the related management's discussion and analysis, which are available for review on SSC's SEDAR+ profile at www.sedarplus.ca.
Jeff Swainson, President and CEO of SSC, stated: "Q1 2025 was a strong quarter for SSC with the closing of the Humble acquisition, which vertically integrated our operations into cultivation, the closing of an over subscribed $6.0 million convertible debenture offering, achieving record gross revenue and adjusted EBITDA, the expansion of our asset base from $10.9 million in Q1 2024 to $57.8 million in Q1 2025, and subsequent to quarter end, significantly improving our balance sheet with the repayment of $3.4 million, the discharge of $0.5 million, and the deferral of $3.25 million of debt. Our steadfast focus for 2025 is to leverage our portfolio of assets to maximize profitability, cash flow from operations, and balance sheet strength, while achieving a lower cost of capital."
Q1 2025 Financial Highlights:
INCOME STATEMENT FIGURES
Q1 2025
Q1 2025
ANNUALIZED
Q1 2024
Q1 2024
ANNUALIZED
% INCREASE
Gross Revenue
$12.4M
$49.6M
$3.1M
$12.4M
298 %
Gross Revenue/Share
$0.115
$0.459
$0.064
$0.258
78 %
Net Revenue
$9.9M
$39.6M
$2.3M
$9.2M
330 %
Net Revenue/Share
$0.091
$0.365
$0.047
$0.190
93 %
Gross Margin
$4.8M
$19.2M
$1.1M
$4.4M
331 %
Gross Margin/Share
$0.044
$0.178
$0.023
$0.092
94 %
EBITDA (1)
$9.5M
Not Annualized (2)
$0.6M
$2.4M
1,451 %
EBITDA/Share
$0.087
Not Annualized (2)
$0.012
$0.050
595 %
Adjusted EBITDA (1)
$3.2M
$12.8M
$0.6M
$2.4M
417 %
Adjusted EBITDA/Share
$0.030
$0.120
$0.012
$0.050
131 %
Net Income
$8.4
Not Annualized (2)
$0.5M
$2.0M
1,573 %
Net Income/Share
$0.078
Not Annualized (2)
$0.010
$0.041
650 %
Normalized Net Income (NNI) (1)
$1.6
$6.4M
$0.5M
$2.0M
500 %
NNI/Share
$0.014
$0.057
$0.010
$0.041
38 %
Cash from Operations Prior to Changes in Working Capital
$2.0M
$8.0M
$0.6M
$2.4M
233 %
Gross Margin %
48.7 %
48.7 %
48.6 %
48.6 %
0 %
(1)
Non-IFRS financial measure. See discussion in the Non-IFRS Financial Measures advisories section of this press release below.
(2)
Not annualized as $7.7 million bargain purchase gain is non-recurring and skews figures.
The results above include the consolidated operations of SSC and its wholly owned subsidiaries Massive Hash Factory Ltd., CannMart Inc. (acquired on September 12, 2024), ANC (acquired on October 18, 2024, effective October 1, 2024), and Humble (acquired on February 28, 2025, adding 1 month of operating results). SSC is continuing to capture synergies in respect of these acquisitions to further reduce costs.
Continued Rationalization and Cost Savings
During late Q1 2025, SSC continued to restructure operations to capture acquisition synergies. This restructuring reduced headcount by approximately 58 during March 2025, reducing annualized payroll costs by approximately $2,500,000. These amounts exclude headcount reductions made prior to closing the Humble acquisition. SSC has identified further restructuring opportunities with an estimated cost savings of between $500,000-$1,000,000 per year.
Q1 2025 Operational Highlights
$6.0 million Convertible Debenture Financing: On February 13, 2025, SSC completed a $6.0 million financing through the issuance of 6,000 debenture units (" Debenture Units") pursuant to an offering (the " Offering") at a price of $1,000 per Debenture Unit. Each Debenture Unit is comprised of one $1,000 principal value secured convertible debenture of SSC (" Debentures") and 1,000 common share purchase warrants of SSC (the " Warrants"). The Debentures are convertible into SSC common shares (" Common Shares") at $1.00 per Common Share at the option of the holder and at any time during the term of the Debentures. Interest accrues on the Debentures at 11% per annum, which interest is payable quarterly in cash by SSC. The Debentures mature on the date which is 48 months from the closing date, are secured by all present and after acquired property of SSC and its subsidiaries, and are subordinated to the Notes (defined below). A total of 6,000,000 Warrants were issued pursuant to the Offering. Each Warrant is exercisable for one Common Share at a price of $1.20 per Common Share for a period of four years from the closing date. The Debentures, Warrants and underlying Common Shares were subject to a hold period of four months and one day from the closing date. 350 Debenture Units (for gross proceeds of $350,000) were issued to Note holders for partial settlement of the Note balance outstanding.
Acquisition of Humble: On February 28, 2025, SSC acquired all the issued and outstanding shares of Delta 9 Bio-Tech (now Humble) for cash consideration of $3,000,000 (" Acquisition"). In connection with the Acquisition, SSC entered into a lease agreement on closing in respect of the Facility (defined below) with an arms-length party for a 10-year term with renewal options. Humble operates a 98,000 square foot GACP certified cannabis cultivation facility in Winnipeg, Manitoba (the " Facility"), with an annual cultivation capacity of approximately 8,000-9,000kg of dried cannabis flower and trim. Humble services the recreational dried flower markets in Ontario, Alberta, Manitoba, Saskatchewan, British Columbia, and the Maritimes, and the business-to-business wholesale market in Canada and internationally. Key anticipated benefits and synergies are as follows:
Low Cultivation Costs: Upon capture of synergies and optimization, it is expected that the all-in cash cost to cultivate will be approximately $0.70 per gram, among the lowest for indoor cannabis in Canada.
No Liabilities: As Humble was acquired through CCAA proceedings, SSC assumed no liabilities upon closing of the Acquisition.
Tax Pools: Humble has approximately $60 million of accrued non-capital loss tax pools which may be usable to SSC. Should these tax pools be utilized, they are expected to reduce future tax payments by up to $12 million at an effective tax rate of 20%.
International Exposure: The Facility is GACP certified, allowing for the export of dried flower to international markets, which currently attracts higher selling prices.
Complimentary Products: The Acquisition allows SSC to participate in the dried flower product category, which is the largest cannabis product category in Canada with a market share of approximately 40% (according to Headset data).
Supply Chain: In the opinion of SSC, the supply demand dynamic is balancing in the Canadian wholesale cannabis marketplace, making it more difficult to procure the inputs that SSC requires. The Acquisition secured a supply of high-quality flower and trim for use in SSC's prerolls and in the manufacturing of concentrates and hash.
Prerolling: Humble sells regular and infused prerolls in numerous markets. SSC's subsidiary ANC Inc. brings this manufacturing in-house, maximizing efficiency.
Vapes: Humble sells vape cartridges in numerous markets. This manufacturing has come in-house at SSC's Massive Hash Factory facility, reducing production costs.
Inventory Velocity: Humble sells several products that SSC manufactures, including hash, which helps maximize inventory turnover.
Facility Cost Savings: SSC will be able to rationalize the activities performed at its various facilities, reducing fixed operating costs by approximately $750,000 annually once rationalized.
Cost Synergies: Administration, including but not limited to public company costs, accounting, IT, governance, and HR are shared, reducing costs significantly.
Blended Excise Rate: Humble pays lower excise rates as a cultivator, which lowers SSC's overall corporate blended excise tax rate.
Repayment of $3.4 Million of ANC Promissory Notes & Deferral of Remainder: Subsequent to Q1 2025, $3.4 of the maximum remaining $7.15 million combined ANC Promissory Note and Reserve Earnout Promissory Note (collectively, the " Notes") were repaid through the issuance of 6,875,000 common shares of SSC at $0.50 per common share (subject to TSXV approval). $0.5 million of the Notes were discharged, $1.0 million of the Notes are now payable on June 3, 2026, and $2.2 million (" Payments Balance") of the Notes are payable with average weekly payments of $21,370.19 over two years. Should SSC repay the $2.2 million Payments Balance by July 31, 2025, the remaining principal balance owing at that time will be reduced by $367,500. Should SSC repay this balance by December 31, 2025, the remaining principal balance owing at that time will be reduced by $245,000. The equity issued is subject to a hold period of four months and one day from the date of issuance. This transaction significantly de-levered SSC's balance sheet.
About Simply Solventless Concentrates Ltd.
SSC is a public company incorporated under the Business Corporations Act (Alberta). SSC's mission is to provide pure, potent, terpene-rich ready to consume cannabis products to discerning cannabis consumers. For more information regarding SSC, please see www.simplysolventless.ca.
Notice on Forward Looking Information
This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "will", "estimates", "believes", "intends", "expects", "projected", "approximately" and similar expressions which are intended to identify forward-looking statements. More particularly and without limitation, this press release contains forward looking statements concerning continued organic revenue growth, the continued synergies expected from integrating CannMart Inc., ANC, and Humble into SSC's operations, capitalizing on SSC's business plan and SSC's expected growth, results of operations and performance. SSC cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of SSC, including expectations and assumptions concerning SSC, the timing and market acceptance of products, competition in SSC's markets, SSC's reliance on customers, fluctuations in interest rates, SSC's ability to maintain good relations with its customers, employees and other stakeholders, changes in law or regulations, SSC's ability to protect its intellectual property, as well as other risks and uncertainties, including those described in SSC's filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of SSC. The reader is cautioned not to place undue reliance on any forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
The forward-looking statements contained in this press release are made as of the date of this press release, and SSC does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by securities law.
This press release contains future-oriented financial information and financial outlook information (collectively, "FOFI") about cost saving and rationalization and restructuring (payroll and other), gross revenue, adjusted EBITDA and NNI of SSC, which are subject to the same assumptions, risk factors, limitations and qualifications as set forth in the above paragraphs. FOFI contained in this document was approved by management as of the date of this document and was provided for the purpose of providing further information about SSC's future business operations. SSC and its management believe that FOFI has been prepared on a reasonable basis, reflecting management's best estimates and judgments, and represent, to the best of management's knowledge and opinion, SSC's expected course of action. However, because this information is highly subjective, it should not be relied on as necessarily indicative of future results. SSC disclaims any intention or obligation to update or revise any FOFI contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this document should not be used for purposes other than for which it is disclosed herein. Differences in the timing of capital expenditures or revenues and variances in production estimates can have a significant impact on the key performance measures included in SSC's guidance. SSC's actual results may differ materially from these estimates.
Non-IFRS Financial Measures
This press release includes references to "working capital", "current ratio", "inventory turnover", "EBITDA", "adjusted EBITDA" and "normalized net income", which are not defined under International Financial Reporting Standards (IFRS). The intent of these non-IFRS measures is to provide additional useful information to investors and analysts. These non-IFRS measures do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other entities. As such, these non-IFRS measures should not be considered in isolation or used as a substitute for measures of performance prepared in accordance with IFRS.
Working capital is an indicative measure of SSC's ability to service its short-term financial obligations with short-term assets. Management believes this measure provides useful information about SSC's current short-term liquidity. Refer to "Liquidity and Capital Resources" for a detailed calculation of this measure in SSC's Q1 2025 MD&A.
Current ratio is calculated by dividing current assets by current liabilities and is meant to indicate whether a company is capable of servicing its current liabilities.
Inventory turnover is calculated by dividing cost of goods sold by inventory, and is meant to indicate how efficient a company is at turning inventory into cash.
EBITDA is calculated as income before interest and finance costs, taxes, depreciation and amortization expenses. EBITDA is considered as a useful measure by management of SSC to understand the profitability of SSC excluding the effects of capital structure, taxation and depreciation, but may not be appropriate for other purposes. EBITDA is considered a useful measure by management to understand profitability excluding the effects of capital structure, taxation and depreciation, but may not be appropriate for other purposes.
Adjusted EBITDA is not defined under IFRS and therefore should not be considered an alternative to, or more meaningful than net income (loss) and comprehensive income (loss). Adjusted EBITDA is calculated as net income before interest and finance costs, taxes, depreciation and amortization expenses, share based compensation, gain settlement or disposal or bargain purchase gains, non-recurring restructuring costs and acquisition costs, foreign exchange gains and losses and government rebates, and other gains or costs that are expected to be non-recurring. Adjusted EBITDA is considered a useful measure by management to understand profitability excluding the effects of capital structure, taxation and depreciation, and non-recurring items, but may not be appropriate for other purposes.
NNI is considered as a useful measure by management of SSC to understand the profitability of SSC excluding the effects of certain non-operating items. NNI is calculated as net income less gain settlement or disposal or bargain purchase gains, non-recurring restructuring costs and acquisition costs, foreign exchange gains and losses and government rebates, income tax recovery, and other gains or costs that are expected to be non-recurring.
See the " Operations" section in SSC's management's discussion & analysis for Q1 2025 and the year ended December 31 2024, available on SEDAR+ at www.sedarplus.ca, for a quantitative reconciliation of net income to adjusted EBITDA for such period, which information is incorporated by reference in this press release. Shown below is a reconciliation of EBITDA, adjusted EBITDA and NNI for Q1, 2025.
Reconciliation of Non-GAAP Measures
EBITDA and Adjusted EBITDA
For the Three Months Ended
March 31,
2025
March 31,
2024
Net and comprehensive income
$ 8,408,008
$ 502,536
Non-operating items:
Depreciation and amortization
587,091
13,234
Finance costs
558,221
51,832
Income tax recovery
(97,214)
-
EBITDA
9,456,106
567,602
Non-operating items:
Restructuring costs
551,175
-
Acquisition costs
372,316
-
Foreign exchange loss
15,175
-
Government rebates
28,786
-
Bargain purchase acquisition price
(7,725,913)
-
Share compensation expense
552,237
43,969
Adjusted EBITDA
$ 3,249,882
$ 611,571
Normalized Net Income
For the Three Months Ended
March 31,
2025
March 31,
2024
Net and comprehensive income
$ 8,408,008
$ 502,536
Non-operating items:
Restructuring costs
551,175
-
Acquisition costs
372,316
-
Foreign exchange loss
15,175
-
Government rebates
28,786
-
Bargain purchase acquisition price
(7,725,913)
-
Income tax recovery
(97,214)
43,969
Normalized net income
$ 1,552,333
$ 546,505
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Simply Solventless Concentrates Ltd.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
China Mobile and ZTE win the Asia Mobile Award 2025 with AI-driven 5G cloudified core network
China Mobile and ZTE have developed the innovative AI-driven green and energy-saving 5G cloudified core network project to reduce the energy consumption and improve the network performance and operation efficiency The AI-driven green and energy-saving 5G cloudified core network innovative and replicable solution helps operators reduce OPEX and CAPEX while achieving significant energy saving effect SHANGHAI, June 20, 2025 /CNW/ -- ZTE Corporation ( / a global leading provider of integrated information and communication technology solutions, in partnership with China Mobile, has earned "Best Mobile Innovation for Climate Action in Asia" award for their AI-driven green and energy-saving 5G cloudified core network innovation project at the Asia Mobile Awards(AMOs) during MWC Shanghai 2025. Energy conservation, emission reduction and green transformation in the communications industry are key issues in the global shift towards green and sustainable development. The innovative AI-driven green and energy-saving 5G cloudified core network project aims to significantly reduce the energy consumption of the 5G core network while enhancing network performance and operation efficiency through the innovative cloud-native architecture and intelligent energy-saving technology. Leveraging ZTE's leading Intelligent 5G core network solutions and China Mobile's extensive experience in green communications, this project successfully achieves energy efficiency optimization and carbon emission reduction of 5G core network, providing operators with efficient and environmentally-friendly 5G core network deployment solutions. The AI-driven green and energy-saving 5G cloudified core network innovation project not only helps operators reduce OPEX and CAPEX, but also provides replicable solutions for the sustainable development of global 5G core networks. To date, this project has been deployed across multiple provinces of China, achieving significant energy savings. Moving forward, ZTE will further its collaboration with China Mobile to promote the application of green and energy-saving technologies in a wider range of network systems. Both parties will work together with global partners to advance the green and intelligent development of 5G networks, with great commitment to the sustainable development of the global communications industry. ABOUT ZTE: ZTE connects the world with continuous innovation for a better future. The company provides innovative technologies and integrated solutions, and its portfolio spans communication networks, computing infrastructure, industry digital solutions, and personal and home smart terminals. Serving over a quarter of the world's population, ZTE is dedicated to leading globally in connectivity and intelligent computing, enabling communication and trust everywhere. ZTE is listed on both the Hong Kong and Shenzhen Stock Exchanges.
Cision Canada
2 hours ago
- Cision Canada
TrinaTracker Ranks Among Top 3 in Key European Solar Tracker Markets According to Wood Mackenzie
CHANGZHOU, China, June 20, 2025 /CNW/ -- The renowned research institution Wood Mackenzie has released its Global solar PV tracker market share report 2025, ranking TrinaTracker sixth globally and fourth in major regions including Europe, the Middle East, Latin America, and Asia Pacific. These results align with the company's strategy of delivering high-quality tracker solutions while focusing on premium markets. Top 4 in Europe, TOP 3 in Spain and Italy The report highlights TrinaTracker's position as the fourth-leading provider in the European market, with particularly strong performance in Spain and Italy, where TrinaTracker ranks third. Europe emerged as TrinaTracker's second-largest market in 2024, accounting for 29.2% of its total shipments. Beyond shipment volume, Europe serves as a key hub for TrinaTracker's flagship projects showcasing its latest technological innovation. For instance, at the Campina project in Spain, TrinaTracker partnered with third-party UL to conduct field tests on its self-developed SuperTrack smart tracking algorithm. The results demonstrated a 2.21% boost in solar plant performance on average, with an impressive 9.15% improvement on typical cloudy days. Rapid Expansion in the Middle East The Middle East saw solar tracker shipments surge to 15.449 GW in 2024, more than doubling from the previous year. Saudi Arabia dominated the region as the largest market, contributing over 12 GW. TrinaTracker ranks fourth in the region, driven by major projects in the UAE and Saudi Arabia. In early 2025, TrinaTracker announced the opening of a 3 GW factory in Saudi Arabia and the delivery of its Vanguard 1P trackers to the PIF4 Al Khushaybi PV Project, further accelerating its growth in the region. Till end of Q1 2025, TrinaTracker has cumulatively delivered around 30GW of its smart mounting systems to more than 60 countries. Through years of operation, TrinaTracker has garnered widespread praise for its products and services. This year, the company aims to strengthen its global presence by offering localized, low-LCOE solar tracker solutions, anticipating steady business growth in the years ahead.
Cision Canada
4 hours ago
- Cision Canada
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces that it has amended the terms of its brokered private placement LIFE financing (the " Offering") previously announced on May 30, 2025, and filed an amended offering document (the " Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units (" Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
